Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Status:
Completed
Trial end date:
2018-10-25
Target enrollment:
Participant gender:
Summary
Apremilast is a new, orally available, small molecule drug that specifically inhibits
phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical
study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.